Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J.
Oñate G, et al. Among authors: garcia a.
Blood Cancer J. 2025 Jan 11;15(1):4. doi: 10.1038/s41408-024-01205-5.
Blood Cancer J. 2025.
PMID: 39799145